EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

All NewsApril 17, 2025

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Ford and GM see savings drivers may pay for later

Walmart is selling a $460 8-person inflatable hot tent safe for wood-burning stoves for 48% off

AI agents’ growing role in payments raises an awkward question

EIA weekly US crude oil inventories -865K vs +877K expected

JCPenney makes big move to win back holiday shoppers after store closures